Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes

被引:16
|
作者
Schneider, Andreas [1 ,2 ]
Schneider, Markus P. [2 ,3 ]
Scharnagl, Hubert [4 ]
Jardine, Alan G. [2 ]
Wanner, Christoph [1 ]
Drechsler, Christiane [1 ]
机构
[1] Univ Hosp Wuerzburg, Div Nephrol, Dept Med, Wurzburg, Germany
[2] Univ Glasgow, Inst Cardiovasc & Med Sci, Renal Res Grp, British Heart Fdn BHF,Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
[3] Univ Hosp Erlangen, Dept Nephrol & Hypertens, Erlangen, Germany
[4] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria
关键词
STIMULATING AGENTS; ANEMIA; HEMOGLOBIN; PROTEIN; DISEASE;
D O I
10.1186/1471-2369-14-67
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification in these patients. Methods: A post-hoc analysis was conducted of the 4D study, including 1015 patients with type 2 diabetes undergoing hemodialysis. Determinants of ESA resistance were identified by univariate logistic regression analyses. Subsequently, multivariate models were performed with stepwise inclusion of significant predictors from clinical parameters, routine laboratory and specific biomarkers. Results: In the model restricted to clinical parameters, male sex, shorter dialysis vintage, lower BMI, history of CHF, use of ACE-inhibitors and a higher heart rate were identified as independent predictors of ESA resistance. In regard to routine laboratory markers, lower albumin, lower iron saturation, higher creatinine and higher potassium levels were independently associated with ESA resistance. With respect to specific biomarkers, higher ADMA and CRP levels as well as lower Osteocalcin levels were predictors of ESA resistance. Conclusions: Easily obtainable clinical parameters and routine laboratory parameters can predict ESA resistance in diabetic hemodialysis patients with good discrimination. Specific biomarkers did not meaningfully further improve the risk prediction of ESA resistance. Routinely assessed data can be used in clinical practice to stratify patients according to the risk of ESA resistance, which may help to assign appropriate treatment strategies. Clinical trial registration: The study was registered at the German medical authority (BfArM; registration number 401 3206). The sponsor protocol ID and clinical trial unique identified number was CT-981-423-239. The results of the study are published and available at http://www.ncbi.nlm.nih.gov/pubmed/16034009.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Predicting type 2 diabetes
    Kang, Seema
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (01): : 13 - 13
  • [42] The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis
    Yuichi Terawaki
    Takashi Nomiyama
    Yuko Akehi
    Hiromasa Takenoshita
    Ryoko Nagaishi
    Yoko Tsutsumi
    Kunitaka Murase
    Hisahiro Nagasako
    Nobuya Hamanoue
    Kaoru Sugimoto
    Ayako Takada
    Kenji Ito
    Yasuhiro Abe
    Yoshie Sasatomi
    Satoru Ogahara
    Hitoshi Nakashima
    Takao Saito
    Toshihiko Yanase
    Diabetology & Metabolic Syndrome, 5
  • [43] Prevalence and associations of low plasma erythropoietin in patients with Type 2 diabetes mellitus
    Mojiminiyi, O. A.
    Abdella, N. A.
    Zaki, M. Y.
    El Gebely, S. A.
    Mohamedi, H. M.
    Aldhahi, W. A.
    DIABETIC MEDICINE, 2006, 23 (08) : 839 - 844
  • [44] Transthyretin Predicts Cardiovascular Outcome in Hemodialysis Patients With Type 2 Diabetes
    Henze, Andrea
    Espe, Katharina M.
    Wanner, Christoph
    Krane, Vera
    Raila, Jens
    Hocher, Berthold
    Schweigert, Florian J.
    Drechsler, Christiane
    DIABETES CARE, 2012, 35 (11) : 2365 - 2372
  • [45] Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 Diabetes
    Kazempour-Ardebili, Sara
    Lecamwasam, Varunika L.
    Dassanyake, Thushara
    Frankel, Andrew H.
    Tam, Frederick W. K.
    Dornhorst, Anne
    Frost, Gary
    Turner, Jeremy J. O.
    DIABETES CARE, 2009, 32 (07) : 1137 - 1142
  • [46] Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus
    Michael Müller
    Carl-Ludwig Schönfeld
    Tanja Grammer
    Vera Krane
    Christiane Drechsler
    Bernd Genser
    Thomas Kohnen
    Christoph Wanner
    Winfried März
    Scientific Reports, 10
  • [47] Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes
    Saito, Osamu
    Saito, Takako
    Asakura, Shinji
    Akimoto, Tetsu
    Inoue, Makoto
    Ando, Yasuhiro
    Muto, Shigeaki
    Kusano, Eiji
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2012, 10 (02) : 464 - 469
  • [48] Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus
    Mueller, Michael
    Schoenfeld, Carl-Ludwig
    Grammer, Tanja
    Krane, Vera
    Drechsler, Christiane
    Genser, Bernd
    Kohnen, Thomas
    Wanner, Christoph
    Maerz, Winfried
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [49] The Complex Immunological Alterations in Patients with Type 2 Diabetes Mellitus on Hemodialysis
    Trandafir, Maria-Florina
    Savu, Octavian Ionel
    Gheorghiu, Mihaela
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (13)
  • [50] The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis
    Terawaki, Yuichi
    Nomiyama, Takashi
    Akehi, Yuko
    Takenoshita, Hiromasa
    Nagaishi, Ryoko
    Tsutsumi, Yoko
    Murase, Kunitaka
    Nagasako, Hisahiro
    Hamanoue, Nobuya
    Sugimoto, Kaoru
    Takada, Ayako
    Ito, Kenji
    Abe, Yasuhiro
    Sasatomi, Yoshie
    Ogahara, Satoru
    Nakashima, Hitoshi
    Saito, Takao
    Yanase, Toshihiko
    DIABETOLOGY & METABOLIC SYNDROME, 2013, 5